Thieme Chemistry has announced that 'Pharmaceutical Substance' version 3.7 is now available. This substantial new release for the reference guide includes 25 new pharmaceutical compounds such as Sofosbuvir and Simeprevir, both used for the treatment of hepatitis C infections.
The new release contains 25 new active pharmaceutical ingredients including four protein kinase inhibitors for oral cancer therapy: Afatinip for the treatment of non-small cell lung cancer and two drugs for the treatment of metastatic melanoma, the BRAF inhibitor Dabrafenib and the MEK inhibitor Trametinib, which are recommended for use in combination. Ibrutinip, the first inhibitor of Brutons tyrosine kinase, is used for indications such as mantle cell lymphoma and chronic lymphocytic leukemia. Additionally, monographs for the hepatitis C cures Sofosbuvir and Simeprevir were added.
'Pharmaceutical Substances' is projected as an invaluable resource for everyone involved in the design, discovery, development and evaluation of drugs. Institutional access is granted after purchasing an annual license, prices depending on the number of potential users.
